

CME/CPD Accreditation:

- Hong Kong College of Radiologists, 1 (Cat. A) CME/CPD point
- At Registration link, please click "I agree" box to consent to sharing your contact details with your local Mundipharma for CME/CPD arrangement

YOU'RE INVITED:

CARBOPLATIN & OXALIPLATIN-BASED REGIMENS: SHOULD NK1RA* BE USED?

AGENDA (1 HOUR):

- 8:00 – 8:35pm Presentation on Carboplatin & Oxaliplatin-Based Regimens: Should NK1RA* be used?
- 8:35 – 8:45pm Case sharing
- 8:45 – 9:00pm Q&A



SPEAKER: PROFESSOR KARIN JORDAN

Department of Haematology and Oncology
University Hospital Heidelberg, Germany

Professor Jordan has served as a board member of MASCC/ESMO Antiemetic Guideline Consensus Panel since 2009, and is in the ASCO antiemetic guideline panel. She holds the co-chair of Supportive Care section of the ESMO Clinical Practice Guidelines and also a member of the Guidelines Steering Committee. Since 2014, she serves as an Associate Editor of Annals of Oncology and since 2018 as a member of the Editorial Board of ESMO Open.

Professor Jordan is a member of the ESMO Council and Chair of the Educational Committee and a member of the Leadership Generation Task Force. She is a Subject Editor for the Supportive Care section of the ESMO Clinical Practice Guidelines and also a member of the Guidelines Steering Committee. Since 2014, she serves as an Associate Editor of Annals of Oncology and since 2018 as a member of the Editorial Board of ESMO Open.

Professor Jordan has authored and co-authored more than 200 publications and her major area of interest is supportive care with a special focus on antiemetic treatment of chemotherapy-induced nausea and vomiting and side effects of new drugs.

OVERVIEW:

The NCCN has recently reclassified Carboplatin emetogenicity according to the AUC (target area under the concentration versus time curve) with a carboplatin AUC ≥ 4 classified as highly emetogenic.¹

Oxaliplatin, on the other hand, is classified as moderately emetogenic chemotherapy (MEC) but may be considered highly emetogenic in certain patients.¹

In this webinar session, we will be discussing whether NK1RA should be considered in patients who are receiving Carboplatin or Oxaliplatin-based regimens.

Reference: 1. NCCN clinical practice guidelines in oncology, Antiemesis V1. 2021. Available at: www.nccn.org/

* NK1RA: Neurokinin-1 Receptor Antagonist; NCCN: National Comprehensive Cancer Network;
ASCO: American Society of Clinical Oncology; MASCC: Multinational Association for Supportive Care in Cancer

For enquiries, please contact Mundipharma for further details:

Mundipharma (Hong Kong) Limited

Units 801B-802A, 8/F, Tower B, Manulife Financial Centre, 223-231 Wai Yip Street, Kwun Tong, Kowloon
Tel: 852 3929 4666 Fax: 852 3929 4668



**25 September 2021
Saturday**



8.00 - 9.00 pm HKT

**CLICK HERE
OR
SCAN FOR
REGISTRATION**



Please fill with your FULL NAME registered under your college or association for CME/CPD accreditation purpose.

Organized by : Sponsored by :

